Eurofins Scientific SE · EURONEXT:ERF

Eurofins Scientific — Investor Day (November 2023)

58 slides from Eurofins Scientific's investor day presentation, Nov 9, 2023

  1. Slide 1: 2023 North American Investor Day

    CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af

  2. Slide 2: Disclaimer

    Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on

  3. Slide 3: Eurofins: The World Leader in Testing for Life

    Eurofins: The World Leader in Testing for Life Key Figures 36 years of value creation • Long-term track record of turning investments into growth, productivity, margin expansion and Return on Capital Employed ca. 900 laboratories 450,000,000+ • Competitive advantages based on tests performed each ye

  4. Slide 4: Eurofins remains very confident in its objectives for organic growth and M&A

    Eurofins remains very confident in its objectives for organic growth and M&A Revenue bridge (2023E to 2027E) Approaching organic M&A €10bn growth organic M&A growth organic M&A growth €6.45bn organic M&A to growth €6.55bn • Continued strong growth outlook in all Eurofins activities average • Increas

  5. Slide 5: Continued strong secular growth outlook in all Eurofins activities

    Continued strong secular growth outlook in all Eurofins activities 2023-2027 objective: 6.5% p.a. average organic growth Revenue share Organic growth Activities in H1 2023 Growth drivers outlook • Rising awareness and demand for food safety & quality • Food and Feed Testing and contamination & pollu

  6. Slide 6: Solid margin performances in North America and Rest of the World, while improvement needed in Europe

    Solid margin performances in North America and Rest of the World, while improvement needed in Europe Europe North America Rest of the World 40% 40% 40% 30% 30% 30% 20% 20% 20% 10% 10% 10% 0% 0% 0% 1 2 2 1 2 2 1 2019 2020 2021 2022 2023E … 2019 2020 2021 2022 2023E … 2019 2020 2 2021 2 2022 2023E … R

  7. Slide 7: Eurofins is developing proprietary automation technologies

    Eurofins is developing proprietary automation technologies and starting to deploy them across its global network Bespoke modular automation platform Attractive financial profile Multi-year investments underway • Significant OpEx for development • Part of CapEx for growth and efficiency Example Conta

  8. Slide 8: Eurofins' proprietary IT solution offers more for clients and costs less

    Eurofins’ proprietary IT solution offers more for clients and costs less than externally available software (example BioPharma Product Testing solutions suite) Eurofins’ proprietary BPT solution Benefits of Eurofins bespoke proprietary IT solutions Advantage: Differentiation and standardisation acro

  9. Slide 9: Disciplined capital allocation has been the foundation of profitable expansion

    Disciplined capital allocation has been the foundation of the profitable expansion of the Core Business1 12 1 Core Business Revenue (€bn) 10 8 COVID-19 Revenue (€bn) 0.6 6 1.4 0.8 Approaching 10 4 6.45 €10bn 6.1 to 4.6 4.6 5.3 6.55 2 3.0 3.8 2.0 2.5 0 1.0 1.2 1.4 2 2012 2013 2014 2015 2016 2017 2018

  10. Slide 10: Eurofins remains committed to its prudent capital allocation strategy

    Eurofins remains committed to its prudent capital allocation strategy centred on growth investments1 Cash flow generation (2019-2022) Investment allocation 2019-2022 (2019-2022) % of sales Maintenance capex Assume ~2.5% of sales Sales €23.4bn Net cash provided by operating activities €4.5bn 19.4% Ac

  11. Slide 11: Investments in start-ups are integral to long-term growth and value creation

    Investments in start-ups are integral to long-term growth and value creation Long track record Strategic rationale Contributions by start-ups in FY 2022 Number of start-ups created Complements M&A strategy: • When acquisitions are too expensive or Organic growth contribution Programme Total Per year

  12. Slide 12: Site ownership has attractive financial fundamentals

    Site ownership has attractive financial fundamentals Benefits Examples • Estimated rent savings of €68m1 in FY 2022 from owned sites 1 Savings • Estimated yield on rent savings from owned sites of 11% (based on net book value at end of 2022 of €635m) • Lower operating costs from investment in renewa

  13. Slide 13: Very healthy leverage and long-term debt maturity profile

    Very healthy leverage and long-term debt maturity profile Leverage1 Debt maturity profile3 (€m) Key Highlights • Net debt decreased from €3,245 at Cash3 the end of FY 2019 to €2,588m2 at 3.2x the end H1 2023 Hybrid (1st call) Schuldschein • 90% of borrowings at fixed rates Eurobond 3 • Stable financ

  14. Slide 14: Our mid-term objectives & drivers

    Our mid-term objectives & drivers (€m) FY 2023 Mid-term objectives & drivers FY 2027 • Average +6.5% organic growth p.a. Revenues €6.45bn – €6.55bn • Potential average revenues from acquisitions of €250m p.a. Approaching €10bn • Organic growth and acquisitions • Align pricing to cost inflation Adj.

  15. Slide 15: Summary

    Summary Continued strong secular growth outlook in all Eurofins activities Long-term track record of disciplined capital allocation to drive growth, productivity, margin expansion and Return on Capital Employed Market leadership Ongoing investment to develop and deploy sector-leading proprietary IT

  16. Slide 16: BioPharma Services

    CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af

  17. Slide 17: BioPharma Services – Comprehensive Global Offering

    BioPharma Services – Comprehensive Global Offering Clinical Development Pre-clinical / BioPharma PSS1 (Central & Agroscience Genomics Discovery Early Product Insourcing Laboratory/ Manufacturing Services Development Testing Solutions Bioanalytical) (CDMO) 20 countries US 40 sites 287 projects US US

  18. Slide 18: Leading Global BioPharma Network

    Leading Global BioPharma Network ~190,000 m2 Leader in significant markets ~130,000 ~5,000 • Global leader in BioPharma Product Testing m2 ~6,000 employees employees • Global leader in Discovery Pharmacology Services 82 • Global leader in Agroscience CRO Services laboratories 32 Europe laboratories

  19. Slide 19: BioPharma Services Evolution

    BioPharma Services Evolution Started Select milestones / acquisitions Market position today 2011: Global infrastructure established (US, Among top 5 global players 2001 Central Laboratory / Bioanalytical Acquisitions: Netherlands, Singapore, China, India) 2005 Genomic Services Acquisitions: Among to

  20. Slide 20: Clients & Peers

    Clients & Peers Major Biopharma companies Innovative biotech Example clients Clients1 + regional & local players Typical contractual ➢ Product Testing: annual master service agreements relationship: ➢ Research & Development Services: project-based agreements Peers + regional & local competitors CONF

  21. Slide 21: Market Update

    Market Update CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 21

  22. Slide 22: State of BioPharma Industry Funding

    State of BioPharma Industry Funding BioPharma Funding1 ($bn) BioPharma Firepower ($bn) (IPOs, Follow-ons, Private and Public/Other) • Biotech funding has normalised in 2022-2023E at levels on par with best 1,422 135 118 levels pre-COVID, as investor willingness to fund promising 68 67 candidates rem

  23. Slide 23: BioPharma Job Openings

    BioPharma Job Openings • Despite high-profile layoffs, overall demand for talent has remained robust despite the normalisation of biopharma funding • Appetite for life sciences talent remains strong, driven by well-funded companies continuing to advance their R&D pipelines • Expect geopolitics to dr

  24. Slide 24: R&D Spend Evolution

    R&D Spend Evolution Worldwide Total Pharmaceutical R&D Spend ($bn)1 Market drivers R&D spend continues to grow substantially, driven by 350 intensity & speed of innovation 289 296 302 • Increased focus on biologics vs. small molecules 300 281 262 272 = increasing amounts spent per drug 249 250 244 •

  25. Slide 25: Large Market Opportunities

    Large Market Opportunities Novel innovations1 Chemicals Biologics Cell and gene therapies Opportunities for Eurofins Description / Complexity2 Increasing complexity in testing and clinical Altering of genetic material trials Traditional, biomarkers, Traditional, biomarkers, genomics, Evidence / Endp

  26. Slide 26: Delivering Value to our Clients

    Delivering Value to our Clients CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 26

  27. Slide 27: Strategic expansion of the BioPharma network

    Strategic expansion of the BioPharma network Expanding capacity across our areas of activity Net floor area (k m2) for BioPharma BioPharma Discovery Genomic CDMO Services Change Product Testing Services Services 400 2018-2022 Dungarvan, IE 350 • Significant Glostrup, DK Homburg, DE investments in fi

  28. Slide 28: DiscoveryAI: Accelerating drug discovery through artificial intelligence

    DiscoveryAI™ Accelerating drug discovery through artificial intelligence DiscoveryAITM can be used to add value throughout the early drug discovery DiscoveryAI potential stages Drug-to-market time: reduced by >20% Predictive accuracy: 75% • Integrated into all Eurofins Integrated Drug Discovery proj

  29. Slide 29: DiscoveryOne: Enabling Drug Discovery Through Integration

    DiscoveryOne™ Enabling Drug Discovery Through the Integration of Our Testing and Consulting Capabilities 10 Eurofins Companies Integrated service offering Strong Growth >5X revenues Acquired 2013 Biotherapeutics & Acquired 2004 Acquired 2012 Chemistry Cell/Gene Therapy Discovery & Development Soluti

  30. Slide 30: Established leading player in Cell and Gene Therapy

    Established leading player in Cell and Gene Therapy with comprehensive client offering and >10 years of experience Successful and long track Supported the development of: record with Cell and Gene • 16 of 24 FDA-approved1 Cell and Gene Therapy Products Therapies (C&GT) • All 6 CAR-T therapies Eurofi

  31. Slide 31: Case study: global CAR-T Cell Therapy partnership

    Case study: global CAR-T Cell Therapy partnership End to end support from development through commercial Strategic use of Eurofins Service models Global Footprint • FFS (Fee For Service) – tactical needs (raw materials, micro, cell banking) Multiple Service Models Facilitating Data Digitization • FT

  32. Slide 32: Eurofins' proprietary IT solution offers more for clients and costs less

    Eurofins’ proprietary IT solution offers more for clients and costs less than externally available software (example BioPharma Product Testing solutions suite) Eurofins’ proprietary BPT solution Benefits of Eurofins bespoke proprietary IT solutions Advantage: Differentiation and standardisation acro

  33. Slide 33: Differentiators

    Differentiators One-stop-service provider with a local, tailored approach to clients; Decentralised & Agile Innovative & R&D Driven Solutions: Specialty solutions for Biologics Customer Support larger clients across multiple countries and continents around the world trust Differentiated delivery mod

  34. Slide 34: CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use

    CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 3434

  35. Slide 35: Food & Feed Testing North American Laboratories Network

    CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af

  36. Slide 36: Eurofins Food & Feed best-in-class hub and spoke network in North America

    Eurofins Food & Feed has built and operates the best-in- class hub and spoke network in North America HUB LABS Des Moines, IA Madison, WI Madison, WI New Orleans, LA Toronto, ON Toronto, ON Los Angeles, CA Minneapolis, MN Madison, WI SPOKE LABS Atlanta, GA Gordon, NE Philadelphia, PA Battle Creek, M

  37. Slide 37: North American 3rd party food testing is a ~$2.5B market with tailwinds

    North American 3rd party food testing is a ~$2.5 B market with tailwinds that accelerated through the pandemic NA 3rd Party Testing & Services $ Billion est 2022 Relevant market trends 2.5 • Supplement/Nutraceutical production 10+% CAGR with desire for healthier, functional foods, sports nutrition i

  38. Slide 38: Competitors

    Eurofins is the clear leader in North America because of our differentiated breadth, science and reputation Competitors Eurofins’ market share1 Small local players1 Other major players #1 share ~2/3 share Chemistry Microbiology Services Science & Reputation Contaminants Nearly 100 years of expertise

  39. Slide 39: Our market position is strong because of many nodes in our network

    Our market position is strong because of many “nodes” in our network and support systems are difficult to copy General micro Difficult-to-copy (across 13+ network node Specialty U.S. regions) GMO testing microbiology Common Lab IT Lab System Single nodes Inter-business price list pricing Allergens S

  40. Slide 40: NA Food & Feed labs take far less capex and have much faster break-even

    NA Food & Feed labs take far less capex and have much faster break-even than our 2017/18 start-up program Madison, WI Hub Des Moines Hub Addition • Opened: January 2021 • Opened: August 2023 • Net floor area: 10,000 sqm • Net floor area: 650 sqm • Incremental build on owned • Build cost: ~$40m • Bui

  41. Slide 41: We expect continued above-market growth with new speed

    We expect continued above-market growth with new speed, and quality standards hard to match without our scale Performance area One-stop shop • Hyper local microbiology laboratories (e.g. meat/produce/supplements) coverage • Niche chemistry: botanical genetics, new contaminants (PFAS) Only in-class •

  42. Slide 42: Summary

    Summary Operate best-in-class Food & Feed Testing network in N. America Provide most comprehensive offering Market Deliver above-market growth from hard-to-copy network leadership Accelerate sales from start-up programs, prudent M&A Disrupt industry even further, setting new standards for food testi

  43. Slide 43: Eurofins Environment Testing US

    CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af

  44. Slide 44: U.S. Market Overview

    U.S. Market Overview CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 44

  45. Slide 45: Macro Trends – ESG Driven Decoupling from GDP

    Macro Trends – ESG Driven Decoupling from GDP ANNUAL GROWTH IN THE ENVIRONMENTAL INDUSTRY 2000 -2024 9% Environment sector growth expected above GDP driven by increasing regulations, social awareness of environmental hazards and demand for sophisticated testing 6% 3% 0% 00 01 02 03 04 05 06 07 08 09

  46. Slide 46: U.S. Environment Market Overview

    U.S. Environment Market Overview Env. Sectors Env. Services Env. Testing Eurofins Env. Testing US $39.2 $76.8 37% $15.5 $501B 48% $239B ~$2.1B (Testing ~1% of services) (Testing ~5% of Consulting & Engineering) $2.1 15% $105 Services Wastewater Treatment Works (WWTW) Analytical >50% of Market yet to

  47. Slide 47: Regulatory/Political Drivers

    Regulatory/Political Drivers Overview U.S. EPA Budget ($B) $10.1 • The US is estimated to spend $150B+ annually $9.6 for ‘Environmental Protection’ – (2% of GDP) $9.1 $9.2 • Drinking Water and Wastewater spend over the next 20 years is estimated to be ~$750B 2020 2021 2022 2023 Bipartisan Infrastruc

  48. Slide 48: PFAS Case Study

    PFAS Case Study CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 48

  49. Slide 49: PFAS in the U.S.

    PFAS in the U.S. 57,000 Presumptive PFAS Contaminated Sites Occurrence Data • At least 45% of the US tap water is estimated to have one or more types of PFAS contamination. • PFOA and PFOS found in many surface water bodies at several folds higher than the US EPA health advisory levels of 4ng/L. • A

  50. Slide 50: PFAS… Not Just an Environmental Issue

    PFAS… Not Just an Environmental Issue… (But all Require Testing) Environmental Products Food Biomonitoring PFAS Regulated Across: PFAS Bans Affecting: Research & Litigation: Research & Litigation Drinking Water, Non-Potable Food Contact Materials, Food Contact Materials CDC, EPA, & Belgium led Water

  51. Slide 51: Evolution of PFAS Regulatory Environment

    Evolution of PFAS Regulatory Environment U.S. EU • Sep 2022: EPA proposed designation of PFOA & PFOS as hazardous substances under CERCLA • Dec 2020: EU Directive states that technical guidelines for PFAS monitoring should be • March 2023: EPA proposed national drinking water established, with the i

  52. Slide 52: Eurofins Environment Testing in the U.S.

    Eurofins Environment Testing in the U.S. CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 52

  53. Slide 53: Eurofins Environment Testing U.S.

    Eurofins Environment Testing U.S. 67 Laboratory Locations ~3,000 Staff (2022) 5M Samples (2022 actual) 550+ Accreditations & Certifications CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an au

  54. Slide 54: Geographic Orientation with Specialty and Drinking Water

    Eurofins Environment Testing U.S. Geographic Orientation with Specialty and Drinking Water Hub & Spoke Model Specialty Services* Sacramento (x2) Knoxville Lancaster St. Louis Burlington Denver Drinking Water Los Angeles South Bend Orlando Built Environment Distributed Model CONFIDENTIALAND PROPRIETA

  55. Slide 55: IT Applications – Development Priorities

    IT Applications – Development Priorities Micro Automation & Data Self Applications AI Visualization Service More agile and mobile Allow users to focus on Provide more metrics and Give clients more control applications to allow for the human element and dashboards to facilitate over their samples bet

  56. Slide 56: Strategic Imperatives & Enablers

    Strategic Imperatives & Enablers Productivity Robotics, Automation, Waste Reduction Technology Detection limits, compounds, matrices, productivity & efficiency People Investment in leaders and development of staff Service On-boarding, data quality turnaround time, testing solutions, digitalization E

  57. Slide 57: Appendix

    Appendix CONFIDENTIALAND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2021]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 57

  58. Slide 58: Definitions / Alternative Performance Measures (APMs)

    Definitions / Alternative Performance Measures (APMs) APMs used in this presentation Adjusted results – reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”. Separately disclosed items (SDI) – include: • one-off costs from integration and reor

Eurofins Scientific — Investor Day (November 2023) on 6ix